NCT02824029View on ClinicalTrials.gov

Ibrutinib in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

May 12, 2023

Study Completion Date

January 8, 2025

Conditions
Classical Hodgkin LymphomaRecurrent Hodgkin LymphomaRefractory Hodgkin Lymphoma
Interventions
DRUG

Ibrutinib

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Correlative studies

Trial Locations (4)

37920

University of Tennessee, Knoxville

48109

University of Michigan Health System, Ann Arbor

48201

Wayne State University/Karmanos Cancer Institute, Detroit

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Barbara Ann Karmanos Cancer Institute

OTHER

NCT02824029 - Ibrutinib in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma | Biotech Hunter | Biotech Hunter